Aims: To assess the effects of 16 weeks of tofogliflozin (sodium-glucose co-transporter-2
| INTRODUCTION
Many patients with type 2 diabetes mellitus (T2DM) have progressive β-cell failure that ultimately requires the use of insulin as part of their treatment regimen. [1] [2] [3] Current treatment guidelines recommend continuation of oral antidiabetic drugs in patients being transitioned to insulin, 4 and nearly all oral antidiabetic drugs, including metformin, sulphonylurea and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been combined effectively with insulin. [5] [6] [7] Sodium-glucose co-transporter-2 (SGLT2) inhibitors are the newest class of oral antidiabetic drug and have several important characteristics that make them attractive for use in combination with insulin. 8 These drugs lower plasma glucose levels by increasing urinary excretion. 8, 9 Their mechanism of action is independent of insulin and their glucose-lowering effects should be expected to complement those of insulin therapy. 8 SGLT2 inhibitors also promote weight loss and reduce blood pressure and are associated with a relatively low risk of hypoglycaemia. 8, 9 The American Diabetes Association guidelines state that adjunctive use of SGLT2 inhibitors may improve glycaemic control and reduce the amount of insulin needed in patients with T2DM 4 ; however, the combination of SGLT2 inhibitors with insulin or sulphonylurea treatment may lead to increases in hypoglycaemia. 10, 11 Tofogliflozin, a highly selective SGLT2 inhibitor, has been approved in Japan for the treatment of T2DM. 12 Clinical trials have
shown that tofogliflozin, when used as monotherapy or in combination with oral antidiabetic agents, significantly decreases glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight and systolic and diastolic blood pressure (BP) in patients with T2DM, while maintaining a low risk of hypoglycaemia. 13, 14 At present, there is no information about the efficacy and safety of tofogliflozin when added to insulin therapy in patients with T2DM. The aim of the present study was to assess the effects of tofogliflozin vs placebo on glycaemic control when added to insulin treatment in terms of HbA1c reduction in patients with T2DM.
| MATERIALS AND METHODS

| Study design
This was a 16-week, randomized, double-blind, placebo-controlled multicentre trial that also included a 36-week extension period (NCT02201004). The study was conducted in 30 diabetes outpatient clinics in Japan. During the 16-week double-blind treatment period, patients with T2DM inadequately controlled on insulin were assigned randomly 2:1 to tofogliflozin 20 mg or placebo once daily (before or after breakfast). Randomization was stratified based on a minimization method including HbA1c level (<8.0% and ≥8.0%), insulin regimen (basal-bolus, bolus, premix, basal) and estimated glomerular filtration rate (eGFR; ≥90, ≥60 to <90, ≥30 to <60 mL/min/1.73 m 2 ) and was conducted via an interactive web response system (IWRS).
The 16-week double-blind treatment period was followed by a and related notices. The study protocol was also approved by local institutional review boards. All patients provided informed written consent.
| Participant inclusion and exclusion criteria
Patients presenting at the diabetes outpatient clinics of the participating investigators were eligible for participation. Participating investigators screened patients for eligibility and entered them into the randomization sequence.
The trial included men and women (aged ≥20 to ≤75 years) with 
| Insulin dosing
The insulin dose was not to be changed during the 16-week doubleblind treatment period unless the patient experienced hypoglycaemia.
The insulin dose could only be reduced if hypoglycaemia occurred or to prevent the occurrence of this adverse event (AE 
| Statistical analyses
Efficacy was assessed in the modified intention-to-treat (mITT) population, which included patients randomized and exposed to at least For the primary efficacy endpoint, sensitivity analyses were performed with imputed value by method of last observation carried forward (LOCF) by means of analysis of covariance and including data collected after rescue therapy using the MMRM model. Subgroup analyses were also performed using the MMRM model.
Responder rates for HbA1c <7.0% and ≤6.5% at week 16 in the two treatment groups were compared using a Cochran-MantelHaenszel test, stratified as described above, and both P values and 95% CIs were determined.
All safety analyses were performed on the safety population, which was defined as all patients randomized and exposed to at least one dose of study treatment.
| Sample size determination
A sample size of 128 patients for the tofogliflozin group and 64 for the placebo group with a 2:1 allocation rate was calculated as sufficient to detect a between-group difference of 0.5% in the absolute change in HbA1c from baseline to week 16 with a power of 90%.
This assumed a common standard deviation of 1.0% at a two-sided 5% significance level. Considering dropout, a total of 210 randomized patients (140 tofogliflozin, 70 placebo) was determined to be necessary.
3 | RESULTS
| Patients
A total of 320 patients were screened and 211 were randomized There were minor differences between treatment groups with respect to several characteristics. Most notably, patients in the tofogliflozin group were older, were more likely to have existing cardiac disorders and had a longer mean duration of disease compared with those who received placebo ( Table 1) .
None of the patients who received tofogliflozin and 2 (2.9%) who were treated with placebo required rescue therapy.
| Efficacy 3.2.1 | Primary endpoint
Treatment with tofogliflozin resulted in a statistically significant decrease in HbA1c from baseline to week 16 compared with placebo (LS mean difference of −1.07%; P < .0001; Figure 2 and Table 2 ). The changes from baseline were −0.59% for tofogliflozin and +0.48% for placebo.
The sensitivity analysis using LOCF and excluding measurements after administration of rescue medication also indicated significant superiority of tofogliflozin over placebo for reduction of HbA1c (LS mean difference of −1.05; P < .0001). This was also the case for analysis of results after receipt of rescue medication (LS mean difference of −1.09; P < .0001).
Subgroup analyses indicated that addition of tofogliflozin to insulin was significantly superior to placebo in patients aged <65 or ≥65 years (LS mean differences of −1.14 and −0.90, respectively, both P < .0001); men and women (LS mean differences of −1.10 and 
| Secondary endpoints
Small percentages of patients in each group achieved HbA1c goals at the end of 16 weeks. For tofogliflozin, 17 patients (12.1%) achieved HbA1c <7.0% and 6 (4.3%) achieved HbA1c ≤6.5%. The respective values for placebo were 1 (1.4%; P = .0075) and 0 (0%; P = .0091).
Tofogliflozin was also significantly superior to placebo for most other secondary endpoints, including body weight (LS mean difference −1.40 kg; P < .0001), FPG (LS mean difference −32.1 mg/dL; P < .0001), PPG (LS mean difference −67.7 mg/dL; P < .0001), diastolic BP (LS mean difference −2.9 mm Hg; P = .0218) and uric acid (LS mean difference −0.29 mg/dL; P = .0062).
| Safety 3.3.1 | AEs
Most patients in both treatment groups experienced ≥1 TEAE (Table 3 ). There were no deaths in either treatment group and 1 patient in each group had an SAE considered to be possibly related to study treatment. 
| TEAEs of special interest
The overall frequencies of patients experiencing TEAEs of special interest was 62 patients (44.3%) for tofogliflozin and 10 patients (14.3%) for placebo ( 
| DISCUSSION
This randomized trial showed that administering tofogliflozin for 16 weeks in Japanese patients with T2DM who were receiving insulin therapy alone or basal insulin plus a DPP-4 inhibitor but had poor glycaemic control, resulted in a significant reduction in HbA1c compared with placebo, along with significant reductions in FPG, PPG, diastolic BP, body weight and uric acid levels. These benefits were observed despite the fact that patients in the tofogliflozin group were older and had a longer mean duration of disease compared with those who received placebo. They were also less likely to be not controlled on diet and exercise alone. 13 These results would suggest that the addition of tofogliflozin to insulin or insulin plus a DPP-4 inhibitor in the present study would not result in a large percentage of patients achieving aggressive HbA1c targets of <7%. The similarity between the HbA1c reductions with tofogliflozin monotherapy and when added to insulin is consistent with the independent mechanisms of action for these two antidiabetic treatments. 20 The improved glyaemic control observed in the present study is similar to that observed in other studies investigating the addition of an SGLT2
inhibitor to insulin treatment in Japanese patients. [21] [22] [23] Canagliflozin,
ipragliflozin and dapagliflozin have all demonstrated greater reductions in HbA1c levels from baseline to 16 weeks when compared with placebo. [21] [22] [23] It has been shown that SGLT2 inhibitors act in the kidney by increasing urinary excretion of glucose; therefore, patients with renal impairment may experience reduced efficacy in terms of Hb1Ac during treatment with SGLT2 inhibitors, particularly those with moderate to severe renal impairment. 24 Dapogliflozin, empagliflozin and ipragliflozin each demonstrated reduced Hb1Ac efficacy in patients with moderate or severe chronic kidney disease. 24 Addition of tofogliflozin to insulin treatment also significantly lowered both FPG and PPG compared with addition of placebo. The effects of tofogliflozin on FPG are consistent with those reported for other SGLT2 inhibitors when added to insulin. 15, 18, [21] [22] [23] Other SGLT2
inhibitors have also been shown to reduce PPG. [25] [26] [27] A study investigating the addition of dapagliflozin to insulin therapy in Japanese patients also demonstrated a significant reduction from baseline in PPG in the treatment group. 22 The ability of tofogliflozin to lower PPG is important because PPG has been shown to be an independent risk factor for macrovascular disease in patients with diabetes. 28 Consistent with other studies, the addition of tofogliflozin to insulin therapy significantly decreased body weight by −1.34 kg vs a slight (0.03 kg) increase with placebo. [21] [22] [23] Weight change may be attributable to a combination of calorie loss in urine and osmotic diureseis. Weight control is an important consideration in the overall management of T2DM and it has been estimated that each −1% reduction in HbA1c achieved with insulin treatment is associated with an~2 kg increase in body weight over 1 year of therapy. 29 Weight gain may worsen insulin resistance, 30 resulting in the need for higher insulin doses. Addition of other SGLT2 inhibitors to treatment has also been shown to decrease insulin dose requirements in patients with T2DM. 15, 31 Tofogliflozin also significantly reduced diastolic BP by −2.9 mm Hg, as well as decreased systolic BP by −2.2 mm Hg, although this decrease was not statistically significant. Reductions in systolic and diastolic BP were also observed when tofogliflozin was administered as monotherapy to patients with T2DM 13 and when other SGLT2
inhibitors were added to insulin therapy. 15, 19 The reductions in BP observed with SGLT2 inhibitors are believed to be attributable to a combination of factors, including osmotic diuresis, natriuresis, weight loss and possible effects of improved endothelial nitric oxide release as a result of better glycaemic control. 32 A recent meta-analysis of clinical trial results for SGLT2 inhibitors has indicated that these agents significantly reduced the risks of all-cause mortality, cardiovascular death, myocardial infarction and heart failure. 33 Results from the EMPA-REG OUTCOME study indicated that patients with T2DM
at high risk of cardiovascular events who received empagliflozin had itor was added to standard care. 34 It was suggested that multiple mechanisms may have contributed to this benefit of SGLT2 inhibition, including reduced arterial stiffness, improved cardiac function and lower myocardial oxygen demand, improvement in renal function, and lowering of uric acid, as well as improved glycaemic control, decreased adiposity and lower blood pressure. 34 The addition of tofogliflozin to insulin therapy had no significant effects on the plasma lipid profile, which is consistent with long-term safety data. 13 In a 52-week safety study investigating tofogliflozin 20 mg as an add-on therapy to various antidiabetic drugs, triglycerides and LDL cholesterol were not significantly changed compared with baseline. Canagliflozin has been reported to increase LDL cholesterol in a dose-dependent manner, so it may be prudent to closely monitor lipid profiles in clinical practice. 13 Tofogliflozin significantly decreased uric acid levels. Elevated uric acid levels have been shown to be a significant risk factor for cardiovascular and renal disease, stroke and all-cause mortality. 35, 36 Hypoglycaemia was the most frequently reported TEAE in both treatment groups. In the present study, the frequency of hypoglycaemia associated with tofogliflozin was higher (~30.0%) than that when tofogliflozin was administered as monotherapy (0% for a 20-mg dose). 13 The increased risk of hypoglycaemia when tofogliflozin was administered with insulin is consistent with results for other SGLT2 inhibitors 15, 18, 19, [37] [38] [39] [40] and with results for other SLGT2 inhibitors in Japanese patients. [21] [22] [23] It is important to note that the insulin dose in the present study could only be changed if FPG was ≥240 mg/dL or patients experienced hypoglycaemia. It is reasonable to suggest that the frequency of hypoglycaemia should decline when patients are permitted to adjust insulin dosing after the addition of tofogliflozin.
This suggestion is consistent with results from a previous study, which showed that addition of tofogliflozin to insulin therapy in patients with poor glycaemic control significantly decreased insulin therapy, permitting a reduction in the daily insulin dose. 41 Safety results indicated that <2% of patients treated with tofogliflozin had genital or urinary tract infections and that 7.1% had excessive urination. Both of these AEs have been associated with administration of SGLT2 inhibitors in previous studies. 8, 16, 41 There were no reports of volume depletion with tofogliflozin in the present study or when it was administered as monotherapy. 13 Patients treated with tofogliflozin reported more AEs related to volume depletion than placebo (7.9% vs 2.9%); however, none led to study discontinuation. In previous studies investigating SGLT2 inhibitors, AEs related to volume depletion have been reported as being higher in the study group compared with the placebo or control group. 8, 16, 41 Patients may be required to maintain adequate fluid intake in these instances. 8 Previously, it has been speculated this difference may be attributable to patients receiving diuretics. 8 It is important to note that the findings of the present study are limited by the short 16-week duration. This period is not sufficient for assessment of the long-term safety of tofogliflozin. The 36-week extension phase will provide safety data to fill this important gap out to 52 weeks of treatment. There were differences between groups for age, duration of disease, neuropathy and whether or not a DPP-4 inhibitor was part of the treatment regimen. Assessment of patients aged ≥65 years and <65 years as part of the subgroup analysis indicated that age did not have an impact on efficacy in terms of HbA1c reduction.
In conclusion, the results from this 16-week double-blind period indicate that addition of tofogliflozin is an effective treatment option for patients with T2DM whose blood glucose is poorly controlled with insulin therapy or with basal insulin combined with a DPP-4
inhibitor. Overall, tofogliflozin demonstrated an acceptable safety profile; an increased risk of hypoglycaemia was observed, but insulin reduction was not permitted during the present study.
